Broncus Medical Inc. (HKG: 2216), a provider of precision intervention solutions for lung diseases with operations in Shanghai and Hangzhou, China, and San Jose and Seattle, United States, has released its financial report for 2023. The company reported product sales of USD 12.41 million for the period, marking a robust 32% increase year-on-year (YOY). Notably, the mainland China market contributed USD 8.62 million to these sales, reflecting an impressive 48% YOY growth.
Throughout 2023, Broncus accelerated the commercialization of its products, focusing on interventional treatments for chronic obstructive pulmonary disease (COPD) and lung cancer. The InterVapor thermal steam therapy system, recognized as the world’s only non-invasive COPD interventional treatment device, was implemented in over 20 hospitals and was accessed or trialed in 100 hospitals across China during the year. Broncus’s real-time navigation products for airway procedures, LungPoint, LungPoint Plus, and LungPro, captured 40% of the market in China.
On the research and development front, Broncus filed the RF II pulmonary radiofrequency ablation system for marketing approval in China. Additionally, the company’s first domestically innovative lung targeted neuroablation (TLD) system for the treatment of acute exacerbation of COPD completed its first pre-market clinical trial surgery in July 2023.- Flcube.com
